UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

Nature biotechnology, 2023-09, Vol.41 (9), p.1296-1306

2023

Volltextzugriff (PDF)

Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors

Clinical cancer research, 2020-12, Vol.26 (24), p.6589-6599

2020

Volltextzugriff (PDF)

Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile

Blood advances, 2024-05, Vol.8 (9), p.2059-2073

2024

Volltextzugriff (PDF)

Translational Model‐Based Strategy to Guide the Choice of Clinical Doses for Antibody–Drug Conjugates

Journal of clinical pharmacology, 2017-07, Vol.57 (7), p.865-875

2017

Volltextzugriff (PDF)

Design of potent and selective GSK3β inhibitors with acceptable safety profile and pharmacokinetics

Bioorganic & medicinal chemistry letters, 2010-04, Vol.20 (7), p.2344-2349

2010

Volltextzugriff (PDF)

Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers

Journal of medicinal chemistry, 2014-02, Vol.57 (3), p.903-920

2014

Volltextzugriff (PDF)

Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2118-2118

2024

Volltextzugriff (PDF)

852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A893-A893

2021

Volltextzugriff (PDF)

Abstract 1785: Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML)

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1785-1785

2018

Volltextzugriff (PDF)

Abstract 2909: CD123-CODV-TCE bispecific T-cell engager for acute myeloid leukemia (AML): Activity on primary AML and safety in non-human primates

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2909-2909

2022

Volltextzugriff (PDF)

Abstract 1198: Characterization of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 expressed at the surface of tumor cells

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1198-1198

2016

Volltextzugriff (PDF)

Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML

Blood, 2023-11, Vol.142 (Supplement 1), p.1418-1418

2023

Volltextzugriff (PDF)

In vivo testing of drug-linker stability

Methods in molecular biology (Clifton, N.J.), 2013, Vol.1045, p.101

2013

Volltextzugriff (PDF)

The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Blood, 2022-11, Vol.140 (Supplement 1), p.9985-9986

2022

Volltextzugriff (PDF)

Design of potent and selective GSK3b inhibitors with acceptable safety profile and pharmacokinetics

Bioorganic & medicinal chemistry letters, 2010-04, Vol.20 (7), p.2344-2349

2010

Volltextzugriff (PDF)

Abstract LB-053: Towards new cryptophycins as promising payloads for ADC

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-053-LB-053

2016

Volltextzugriff (PDF)

Abstract 2960: The novel trifunctional anti-BCMA NK cell engager SAR’514 has potent in-vitro , in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2960-2960

2023

Volltextzugriff (PDF)

Abstract B145: PK/PD evaluation of an anti-CEACAM5 antibody drug conjugate, in a colon patient-derived-xenografted mice model

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B145-B145

2015

Volltextzugriff (PDF)

Abstract 1688: A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1688-1688

2015

Volltextzugriff (PDF)

Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics

Bioorganic & medicinal chemistry letters, 2010-04, Vol.20 (7), p.2344-2349

2010

Volltextzugriff (PDF)

Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa

Nature communications, 2020-01, Vol.11 (1), p.510-510, Article 510

2020

Volltextzugriff (PDF)

The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein―Coupled Receptors

Annual review of pharmacology and toxicology, 2012-01, Vol.52 (1), p.153-178

2012

Volltextzugriff (PDF)

Microplastic inputs to the Mediterranean Sea during wet and dry seasons: The case of two Lebanese coastal outlets

Marine pollution bulletin, 2024-01, Vol.198, p.115781-115781, Article 115781

2024

Volltextzugriff (PDF)

First assessment of microplastics in offshore sediments along the Lebanese coast, South-Eastern Mediterranean

Marine pollution bulletin, 2023-01, Vol.186, p.114422, Article 114422

2023

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(58)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors

Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile

Translational Model‐Based Strategy to Guide the Choice of Clinical Doses for Antibody–Drug Conjugates

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

Design of potent and selective GSK3β inhibitors with acceptable safety profile and pharmacokinetics

Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers

Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models

852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC

Abstract 1785: Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML)

Abstract 2909: CD123-CODV-TCE bispecific T-cell engager for acute myeloid leukemia (AML): Activity on primary AML and safety in non-human primates

Abstract 1198: Characterization of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 expressed at the surface of tumor cells

Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML

In vivo testing of drug-linker stability

The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Design of potent and selective GSK3b inhibitors with acceptable safety profile and pharmacokinetics

Abstract LB-053: Towards new cryptophycins as promising payloads for ADC

Abstract 2960: The novel trifunctional anti-BCMA NK cell engager SAR’514 has potent in-vitro , in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement

Abstract B145: PK/PD evaluation of an anti-CEACAM5 antibody drug conjugate, in a colon patient-derived-xenografted mice model

Abstract 1688: A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors

Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics

Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa

The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein―Coupled Receptors

Microplastic inputs to the Mediterranean Sea during wet and dry seasons: The case of two Lebanese coastal outlets

First assessment of microplastics in offshore sediments along the Lebanese coast, South-Eastern Mediterranean

Suchergebnisse filtern